COMMUNIQUÉS West-GlobeNewswire

Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.
15/06/2026
The new fibrinogen concentrate, approved in the U.S. for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, is now available in the U.S. FESILTY complements Grifols’ bleeding [...]
Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome
15/06/2026
Submission Supports Development of a Potential Non-Surgical Treatment for a Rare Genetic Disorder that Causes Recurrent Basal Cell Carcinomas Beginning in Childhood PHILADELPHIA, June 15, 2026 (GLOBE NEWSWIRE) -- [...]
BVI Expands Commitment to Ophthalmic Education with New Experience Hub in Europe
15/06/2026
New facility expands opportunities for hands-on learning, professional development, and clinical collaboration. BVI plans to expand the Hub's educational offerings through structured programs covering cataract surgery, [...]
KFSH présente un modèle d’IA appliquée au HLTH Europe 2026
15/06/2026
AMSTERDAM, 15 juin 2026 (GLOBE NEWSWIRE) -- Au HLTH Europe 2026, qui se tient à Amsterdam du 15 au 18 juin, King Faisal Specialist Hospital & Research Centre (KFSH) positionne l’IA en radiologie comme l’un des [...]
DOGECOIN CASH FILES UTILITY PATENT FOR BLOCKCHAIN INFRASTRUCTURE DESIGNED TO SUPPORT DOGECOIN APPLICATION USABILITY
15/06/2026
Mesquite, NV, June 15, 2026 (GLOBE NEWSWIRE) -- Mesquite, NV – June 15, 2026 – Dogecoin Cash, Inc. (OTC: DOGP) today announced the filing of a U.S. utility patent application with the United States Patent and Trademark [...]
KFSH Presents Applied Radiology AI Model at HLTH Europe 2026
15/06/2026
AMSTERDAM, June 15, 2026 (GLOBE NEWSWIRE) -- At HLTH Europe 2026, taking place in Amsterdam from June 15 to 18, King Faisal Specialist Hospital & Research Centre (KFSH) is positioning radiology AI as one of the [...]
Bio Usawa Appoints Dr. Aida Habtezion, Former Chief Medical Officer at Pfizer, to its Board of Directors
15/06/2026
KIGALI, Rwanda and SAN FRANCISCO, June 15, 2026 (GLOBE NEWSWIRE) -- Bio Usawa, a biotechnology company dedicated to expanding access to high-quality biologic medicines across Africa, today announced the appointment of [...]
CancerVax Successfully Demonstrates Full Nanoparticle Delivery in Mouse Study
15/06/2026
First biodistribution study of the Company’s complete cancer targeting nanoparticle avoided many healthy organs Lehi, UT, June 15, 2026 (GLOBE NEWSWIRE) -- CancerVax Successfully Demonstrates Full Nanoparticle Delivery [...]
EURneffy 1 mg approved in the UK as the first and only needle-free adrenaline treatment for young children (aged 4 and older, 15–30 kg) at risk of anaphylaxis
15/06/2026
ALK announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for EUR neffy ® 1 mg, the first and only needle-free adrenaline treatment for anaphylaxis for [...]
ENA Respiratory Receives USPTO Notice of Allowance for Two Patents Covering TLR2 Agonists and Rhinovirus-Mediated COPD Exacerbations
15/06/2026
MELBOURNE, Australia, June 15, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory , a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
15/06/2026
COPENHAGEN, Denmark, June 15, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on June 2, 2026, under which the Company will repurchase shares for an amount up to [...]
Intravacc and SynphaBase Announce Strategic Partnership to Advance Conjugate Vaccine Development
15/06/2026
The companies will combine their complementary expertise in synthetic oligosaccharides, conjugation process development and GMP vaccine manufacturing to support partners developing next-generation conjugate vaccines [...]
Intravacc et SynphaBase annoncent un partenariat stratégique visant à faire progresser le développement des vaccins conjugués
15/06/2026
Les deux entreprises uniront leurs compétences complémentaires en matière d’oligosaccharides synthétiques, de développement de procédés de conjugaison et de fabrication de vaccins selon les BPF afin d’accompagner leurs [...]
Enterome presents Phase 1/2 iNHL interim data at EHA demonstrating durable OncoMimics™-induced CD8 T cell responses and clinical activity
15/06/2026
PRESS RELEASE EO2463 was well tolerated in monotherapy and in R 2 combination therapy cohorts EO2463-induced CD8 T cell expansion significantly associated with clinical response across cohorts Data support development [...]
2026 EHA | Over 40 Orelabrutinib Studies Presented, Including First Clinical Data from Europe and US TN CLL/SLL Patients
15/06/2026
BEIJING, June 15, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that over 40 [...]
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
15/06/2026
ZW191 demonstrates compelling anti-tumor activity in platinum-resistant ovarian cancer patients regardless of FRα expression level Confirmed objective response rate (cORR) of 78.6% in FRα-positive (≥75% at PS2+) [...]
Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress
15/06/2026
Poster presentations from ongoing clinical trials of two core assets, olverembatinib and lisaftoclax, highlight global innovation capabilities in hematologic malignancies ROCKVILLE, Md. and SUZHOU, China, June 14, 2026 [...]
Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026
14/06/2026
Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to physiologically normal levels in adults with classic CAH New results from the Phase [...]
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
14/06/2026
Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms Treatment also resulted in stable or reduced pituitary [...]

Pages